Should Value Investors Buy Aveanna Healthcare (AVAH) Stock?

Zacks
Zacks kaynağında aç
Should Value Investors Buy Aveanna Healthcare (AVAH) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels.

Zacks has developed the innovative Style Scores system to highlight stocks with specific traits. For example, value investors will be interested in stocks with great grades in the "Value" category. When paired with a high Zacks Rank, "A" grades in the Value category are among the strongest value stocks on the market today.

One company to watch right now is Aveanna Healthcare (AVAH). AVAH is currently sporting a Zacks Rank #2 (Buy), as well as a Value grade of A. The stock has a Forward P/E ratio of 17.55. This compares to its industry's average Forward P/E of 19.90. AVAH's Forward P/E has been as high as 296.02 and as low as -1,528.95, with a median of 46.39, all within the past year.

Value investors also frequently use the P/S ratio. This metric is found by dividing a stock's price with the company's revenue. This is a preferred metric because revenue can't really be manipulated, so sales are often a truer performance indicator. AVAH has a P/S ratio of 1. This compares to its industry's average P/S of 1.53.

Finally, we should also recognize that AVAH has a P/CF ratio of 31.95. This figure highlights a company's operating cash flow and can be used to find firms that are undervalued when considering their impressive cash outlook. This company's current P/CF looks solid when compared to its industry's average P/CF of 35.94. AVAH's P/CF has been as high as 70.13 and as low as -38.60, with a median of 26.01, all within the past year.

Value investors will likely look at more than just these metrics, but the above data helps show that Aveanna Healthcare is likely undervalued currently. And when considering the strength of its earnings outlook, AVAH sticks out as one of the market's strongest value stocks.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Aveanna Healthcare Holdings Inc. (AVAH): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research